Merck ready for first patent hurdle?
Merck expects to beat top end of analysts consensus estimates for 2000 earnings per share ($2.81), company announces. The projection takes into account an expected rapid drop-off in sales of the ACE inhibitor Vasotec (enalapril) following patent expiration in August, Merck said. The company faces four more significant patent expirations (Mevacor, Pepcid, Prilosec and Prinivil) over the next two years
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth